細胞生存率アッセイ市場 - 世界の産業規模、シェア、動向、機会、予測、製品別、用途別、最終用途別、地域別、競合別、2019～2029年

世界の細胞生存率アッセイ市場は、2023年に9億8,000万米ドルとなり、2029年までのCAGRは8.80%で、予測期間中に目覚ましい成長を示すと予測されています。

細胞生存率アッセイは、細胞の健全性、生存率、全体的な幸福度を評価するために使用される実験技術です。これらのアッセイは、細胞が生きていて、健康で、適切に機能しているかどうか、あるいはストレス、損傷、死を受けているかどうかについての洞察を提供します。細胞生存率アッセイは、調査、製薬、バイオテクノロジー、毒物学、環境科学など様々な分野で、細胞に対する様々な治療、条件、物質の影響を理解するために広く使用されています。アッセイは細胞の代謝を評価するもので、多くの場合、無色の基質から有色の生成物または蛍光分子への変換によって測定されます。健康な細胞は無傷の細胞膜を持っているため、アッセイでは傷ついた細胞膜を透過し、死んだ細胞を染色する色素を使用することがあります。

がんや神経変性疾患などの疾病の蔓延が拡大しているため、新たな治療法や治療法の開発に向けた研究活動が活発化しています。細胞生存率アッセイは、疾患のメカニズムを理解し、潜在的な介入策を検証する上で重要な役割を果たしています。がん研究、幹細胞研究、再生医療などの分野を含むライフサイエンス研究の継続的な進歩には、さまざまな条件下での細胞の生存率や挙動を評価する信頼性の高い方法が必要です。個別化医療へのシフトには、個々の患者の特性に合わせた治療が含まれます。細胞生存率アッセイは、患者の細胞が特定の治療にどのように反応するかを評価するのに不可欠であり、個別化治療アプローチの開発に役立ちます。COVID-19パンデミックのような出来事は、感染症の研究、抗ウイルス化合物の試験、ワクチン候補の評価において、迅速で正確な生存率アッセイの重要性を強調しています。アッセイプラットフォーム、イメージング技術、検出方法における絶え間ない技術革新により、細胞生存率アッセイの感度、精度、スピードが向上し、より汎用的で価値の高いものとなっています。

主要な市場促進要因

創薬と医薬品開発の増加

新興感染症とワクチン

技術の進歩

主要な市場課題

アッセイ性能のばらつき

感度と特異性

主要な市場動向

環境試験

セグメント別の洞察

製品の洞察

エンドユーザーの洞察

地域別の洞察

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 COVID-19が世界の細胞生存率アッセイ市場に与える影響

第5章 顧客の声

第6章 細胞生存率アッセイの世界市場展望

• 市場規模と予測
  • 金額別
• 市場シェアと予測
  • 製品別（消耗品、装置）
  • 用途別（創薬研究開発、幹細胞研究、診断薬）
  • 最終用途別（バイオ医薬品・製薬企業、CRO・CMO、学術・研究機関、診断ラボ）
  • 地域別
  • 企業別（2023年）
• 市場マップ

第7章 アジア太平洋の細胞生存率アッセイ市場展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 製品別
  • 用途別
  • 最終用途別
  • 国別
• アジア太平洋：国別分析
  • 中国
  • インド
  • オーストラリア
  • 日本
  • 韓国

第8章 欧州の細胞生存率アッセイ市場展望

• 市場規模と予測
  • 金額別
• 市場シェアと予測
  • 製品別
  • 用途別
  • 最終用途別
  • 国別
• 欧州：国別分析
  • フランス
  • ドイツ
  • スペイン
  • イタリア
  • 英国

第9章 北米の細胞生存率アッセイ市場の展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 製品別
  • 用途別
  • 最終用途別
  • 国別
• 北米：国別分析
  • 米国
  • メキシコ
  • カナダ

第10章 南米の細胞生存率アッセイ市場の展望

• 市場規模と予測
  • 金額別
• 市場シェアと予測
  • 製品別
  • 用途別
  • 最終用途別
  • 国別
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第11章 中東・アフリカの細胞生存率アッセイ市場展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 製品別
  • 用途別
  • 最終用途別
  • 国別
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第12章 市場力学

• 促進要因
• 課題

第13章 市場動向と発展

• 最近の動向
• 製品上市
• 合併と買収

第14章 細胞生存率アッセイの世界市場SWOT分析

第15章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第16章 PESTLE分析

第17章 競合情勢

• Thermo Fisher Scientific, Inc
• Agilent Technologies, Inc.
• Bio-Rad Laboratories, Inc.
• Merck KGaA
• PerkinElmer Inc.
• Promega Corporation
• Biotium Inc.
• Creative Bioarra
• Abcam plc
• Charles River Laboratories International, Inc

第18章 戦略的提言

第19章 調査会社・免責事項

Global Cell Viability Assays Market was valued at USD 0.98 billion in 2023 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 8.80% through 2029. Cell viability assays are laboratory techniques used to assess the health, viability, and overall well-being of cells. These assays provide insights into whether cells are alive, healthy, and functioning properly or if they are undergoing stress, damage, or death. Cell viability assays are widely used in various fields, including research, pharmaceuticals, biotechnology, toxicology, and environmental science, to understand the effects of different treatments, conditions, or substances on cells. Assays assess cellular metabolism, often measured by the conversion of a colorless substrate into a colored product or a fluorescent molecule. Healthy cells have intact cell membranes, so assays might use dyes that penetrate compromised membranes, staining dead cells.

The growing prevalence of diseases, such as cancer and neurodegenerative disorders, has intensified research efforts to develop new therapies and treatments. Cell viability assays play a critical role in understanding disease mechanisms and testing potential interventions. Ongoing advancements in life sciences research, including fields like cancer research, stem cell research, and regenerative medicine, require reliable methods to assess cell viability and behavior under different conditions. The shift towards personalized medicine involves tailoring treatments to individual patient characteristics. Cell viability assays are essential in evaluating how a patient's cells respond to specific treatments, aiding in the development of personalized therapeutic approaches. Events like the COVID-19 pandemic have underscored the importance of rapid and accurate viability assays for studying infectious diseases, testing antiviral compounds, and evaluating vaccine candidates. Continuous technological innovations in assay platforms, imaging techniques, and detection methods are enhancing the sensitivity, precision, and speed of cell viability assays, making them more versatile and valuable.

Key Market Drivers

Rise in Drug Discovery and Development

In the early stages of drug discovery, researchers screen numerous compounds to pinpoint potential drug candidates. Cell viability assays swiftly evaluate their impact on cell health, aiding in candidate selection. Once promising candidates emerge, these assays gauge their effectiveness in targeting specific disease pathways or cellular processes. They offer insights into differential viability effects on diseased versus healthy cells. Ensuring drug safety is paramount, with cell viability assays used to assess compound toxicity, detecting adverse effects before advancing to further studies.

Determining the dose-response relationship of a drug candidate is crucial for understanding the optimal dosage for therapeutic effect while minimizing toxicity. Viability assays provide information on how a drug candidate affects cellular pathways and processes, aiding in understanding its mechanism of action and therapeutic potential. Personalized medicine requires evaluating individual patient responses to different drug candidates, with viability assays guiding effective treatment options.

Viability assays also validate potential drug targets, helping researchers understand their relevance in disease pathways. The demand for high-throughput screening has led to the development of automated assays, increasing drug discovery efficiency. As biologics and cell-based therapies advance, viability assays play a vital role in assessing cell health and functionality. They also identify potential interactions between drugs, supporting the development of combination therapies, crucial for the Global Cell Viability Assays Market.

Emerging Infectious Diseases and Vaccines

These assays are pivotal in comprehending the impact of infectious agents, assessing potential antiviral compounds, and evaluating vaccine candidates. During outbreaks of emerging infectious diseases like COVID-19, there is an urgent need for effective antiviral drugs. Cell viability assays are crucial for screening compounds to identify those inhibiting viral replication while safeguarding host cells. They aid in understanding antiviral compounds' mechanisms by assessing their effects on infected cells, crucial for optimizing drug candidates and developing targeted therapies. These assays also facilitate the assessment of existing drugs for potential antiviral activity against new infectious agents, expediting drug development using known compounds with established safety profiles.

Also, they are integral in evaluating vaccine efficacy, assessing immune response stimulation, and measuring the ability to prevent infection or reduce viral replication. Adjuvants, which enhance vaccine immune-stimulating effects, are also evaluated for safety and effectiveness using cell viability assays. Determining vaccine immunogenicity, the ability to induce an immune response, is vital for predicting vaccine effectiveness and finding the balance between efficacy and safety. These assays are also employed to assess vaccine stability under various storage conditions, ensuring effectiveness during distribution.

Researchers utilize cell viability assays to study virus effects on cellular health, aiding in understanding infection mechanisms and intervention development. High-throughput screening methods, facilitated by automated assays, are essential for addressing urgent infectious diseases. As new infectious agents emerge, reliable methods such as cell viability assays become crucial for research, thereby driving demand in the Global Cell Viability Assays Market.

Technological Advancements

These advancements have broadened researchers' capabilities in evaluating cell health, screening compounds, and studying diseases more effectively. Label-free assays, like impedance-based assays, track changes in electrical impedance as cells attach, proliferate, or perish. They offer real-time monitoring without external labels, enabling dynamic and non-invasive viability assessment. High-Content Screening (HCS) integrates automated microscopy and image analysis to evaluate multiple cellular parameters concurrently, providing deeper insights into cell behavior. Fluorescent probes and dyes have been developed to target specific cellular components associated with viability, enhancing assay specificity and enabling multiplexing for comprehensive data.

Nanotechnology-based biosensors detect cellular changes at the nanoscale, enabling highly sensitive and specific viability measurements by identifying subtle alterations in cellular physiology. With the rising popularity of 3D cell culture models, viability assays have adapted to assess cell health in these complex environments using techniques like confocal imaging and specialized viability markers.

Microfluidic devices and organ-on-a-chip platforms replicate physiological conditions, offering more realistic viability assessments. They shed light on how cells respond to drugs and toxins in environments resembling the human body. Live-cell imaging, such as time-lapse microscopy, tracks changes in cell viability over time, providing insights into cell health dynamics and treatment responses. Automation has transformed cell viability assays, enhancing throughput and reducing errors through robotic platforms and digital microscopy with advanced image analysis software.

Advancements in single-cell analysis unveil viability heterogeneity within populations, uncovering rare subpopulations with distinct behaviors. Microscale Thermophoresis (MST) measures changes in the movement of fluorescently labeled molecules in response to temperature changes, offering insights into viability-related pathways by assessing binding interactions. Molecular assays, like real-time polymerase chain reaction (PCR), gauge changes in gene expression linked to cell viability, apoptosis, and stress responses. These advancements will accelerate the demand for the Global Cell Viability Assays Market.

Key Market Challenges

Variability in Assay Performance

Different cell lines, even of the same type, can exhibit varying sensitivities to assays due to genetic differences, culture conditions, and intrinsic characteristics. Within a cell population, individual cells can respond differently to treatments or conditions. This heterogeneity can introduce variability in viability measurements. Variations in assay procedures, such as incubation times, reagent concentrations, and detection methods, can lead to inconsistent results between experiments or laboratories. Manual steps in assays can introduce variability due to differences in technique, timing, and subjective judgment. Differences in instruments, such as microplate readers or imaging systems, can lead to variations in measurements, affecting assay consistency. Environmental conditions like temperature and humidity can influence cell behavior and assay outcomes. Variations in these conditions can lead to inconsistent results. Primary cells, cell lines, and patient-derived samples can behave differently in assays, leading to variability. Variability can arise during sample collection, processing, and preparation, affecting assay outcomes.

Sensitivity and Specificity

Achieving the right balance between sensitivity (the ability to detect small changes) and specificity (the ability to accurately identify true positives) is essential for the reliability and relevance of viability assay results. An overly sensitive assay might detect even minor changes in cell behavior that are not biologically relevant. This can lead to false positives and misinterpretation of results. Viability assays should be sensitive enough to detect subtle changes in cell health caused by treatments or conditions, especially in cases where the impact is not immediately obvious. Cells can exhibit dynamic responses to stimuli, including transient changes in viability. Ensuring that an assay can capture these dynamic shifts requires careful design and optimization. Cells within a population can exhibit inherent variability in response to external factors. A sensitive assay should account for this natural variability without generating excessive noise. Lack of specificity can result in false-negative results, where the assay fails to identify actual viability changes. This can lead to missing critical biological responses. Different cell types can respond differently to the same conditions. An assay might be specific in one cell type but not in another, affecting its generalizability. Components of the assay, such as dyes or substrates, can interact with cells or compounds in unintended ways, leading to nonspecific signals.

Key Market Trends

Environmental Testing

Cell viability assays are employed to assess the potential toxic effects of pollutants and chemicals on various organisms present in the environment, including aquatic species and plants. These assays help evaluate the impact of contaminants on the health and survival of these organisms. Environmental testing is not limited to ecological impacts; it also involves assessing the effects of pollutants on human health. Cell viability assays can be used to study how environmental factors influence human cells and tissues, aiding in understanding exposure-related health risks. Environmental contaminants known as endocrine disruptors can interfere with hormone systems and have adverse effects on both wildlife and humans. Cell viability assays are used to study the effects of these disruptors on cellular health and hormone pathways. Cell viability assays are adaptable to assess air and water quality. For example, airborne particulates or waterborne pollutants can be tested using assays designed to measure cellular responses to contaminants. Agricultural chemicals, such as pesticides and herbicides, can enter the environment and affect non-target organisms. Cell viability assays assist in evaluating the toxicity of these chemicals to both target and non-target species. Residues from pharmaceuticals and personal care products can end up in the environment, potentially affecting aquatic ecosystems. Cell viability assays help assess the impact of these residues on aquatic organisms.

Segmental Insights

Product Insights

In 2023, the Global Cell Viability Assays Market dominated by consumables segment in the forecast period and is predicted to continue expanding over the coming years. The usefulness of consumables in numerous pharmaceutical and biopharmaceutical, diagnostic, and stem cell research applications can be credited with this. Additionally, several market participants are providing a large selection of non-toxic, ready-to-use, and high-quality results-immediate cell viability assay reagents.

Luminometric assays are anticipated to witness the fastest growth in the forecast period. Because of their straightforward equipment requirements, straightforward methods, resilience, and exceptional sensitivity. Due to its advantages over colorimetric and dye exclusion assays because they are more sensitive, fluorometric assays held the second-largest share in 2023. All these characteristics make it simple to scale and adapt from bench research to high throughput applications. Such characteristics of the cell viability assay are promoting the growth of the consumables segment.

End-user Insights

In 2023, the Global Cell Viability Assays Market biopharmaceutical and pharmaceutical companies segment held the largest share and is predicted to continue expanding over the coming years. Since viability assays are frequently used in the pharmaceutical industry to assess how developed drugs affect cells. To track the effectiveness of therapies that have been created and frequently target cancer tumours, researchers employ a wide variety of assays. Additionally, a cell viability assay can be used to gauge the compounds' or agents' degrees of toxicity. The segment is driven by the biopharmaceutical and pharmaceutical industries' numerous applications of cell viability assay.

CROs and CMOs are expected to grow at the fastest growth in the forecast period. For a variety of reasons, pharmaceutical companies collaborate with CROs and CMOs. These partnerships may save costs, speed up time to market, and enhance process effectiveness. Collaborations are anticipated to expand the use of cell viability assays across a range of applications, including drug discovery and development, supporting industry growth over the next few years.

Regional Insights

The North America region dominates the Global Breast Cancer Core Needle Biopsy Market in 2023. This significant increase in investment initiatives by the government, the rise in the prevalence of chronic diseases like cancer, and the presence of a top-notch infrastructure for clinical and laboratory research in North America are all factors that contribute to this significant share. For instance, according to Globocanreport, there were almost 612,390 fatalities and 2,281,658 new cancer cases in the U.S. in 2020. As a result, the market's growth possibilities are expanding due to the rising incidence of chronic and infectious diseases as well as the growing emphasis on cell-based treatments.

Asia Pacific is predicted to experience the fastest growth during the projection period. Due to the increasing need for innovative therapies in the region. Other elements promoting regional prosperity include escalating government expenditure in R&D and quickening infrastructure growth. Additionally, funding is being provided to several local players to work on creating a cure for a number of chronic illnesses, including cancer.

Key Market Players

Thermo Fisher Scientific, Inc.

Agilent Technologies, Inc.

Bio-Rad Laboratories, Inc.

Merck KGaA

PerkinElmer Inc.

Promega Corporation

Biotium Inc.

Creative Bioarra

Abcam plc

Charles River Laboratories International, Inc

Report Scope:

In this report, the Global Cell Viability Assays Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Cell Viability Assays Market, By Product:

Consumables

Reagents and Assay Kits, by type

Dye exclusion assays

Colorimetric assays

Fluorometric assays

Luminometric assays

Instruments

Spectrophotometer

Microscopy

Cell imaging and analysis system

Flow Cytometry

Others

Cell Viability Assays Market, By Application:

Drug Discovery and Development Stem Cell Research Diagnostics

Cell Viability Assays Market, By End User:

Biopharmaceutical & Pharmaceutical Companies CROs & CMOs Academic & Research Institutes Diagnostic Labs

Global Cell Viability Assays Market, By region:

North America

United States

Canada

Mexico

Asia-Pacific

China

India

South Korea

Australia

Japan

Europe

Germany

France

United Kingdom

Spain

Italy

South America

Brazil

Argentina

Colombia

Middle East & Africa

South Africa

Saudi Arabia

UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Cell Viability Assays Market.

Available Customizations:

Global Cell Viability Assays Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Impact of COVID-19 on Global Cell Viability Assays Market

5. Voice of Customer

6. Global Cell Viability Assays Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product (Consumables, Instruments)
  • 6.2.2. By Application (Drug Discovery and Development, Stem Cell Research, Diagnostics)
  • 6.2.3. By End Use (Biopharmaceuticals and Pharmaceutical Companies, CROs & CMOs, Academic and Research Institutes, Diagnostic Lab)
  • 6.2.4. By Region
  • 6.2.5. By Company (2023)
• 6.3. Market Map

7. Asia Pacific Cell Viability Assays Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Application
  • 7.2.3. By End Use
  • 7.2.4. By Country
• 7.3. Asia Pacific: Country Analysis
  • 7.3.1. China Cell Viability Assays Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By End Use
  • 7.3.2. India Cell Viability Assays Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By End Use
  • 7.3.3. Australia Cell Viability Assays Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By End Use
  • 7.3.4. Japan Cell Viability Assays Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By End Use
  • 7.3.5. South Korea Cell Viability Assays Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By End Use

8. Europe Cell Viability Assays Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Application
  • 8.2.3. By End Use
  • 8.2.4. By Country
• 8.3. Europe: Country Analysis
  • 8.3.1. France Cell Viability Assays Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By End Use
  • 8.3.2. Germany Cell Viability Assays Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By End Use
  • 8.3.3. Spain Cell Viability Assays Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By End Use
  • 8.3.4. Italy Cell Viability Assays Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By End Use
  • 8.3.5. United Kingdom Cell Viability Assays Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By End Use

9. North America Cell Viability Assays Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Application
  • 9.2.3. By End Use
  • 9.2.4. By Country
• 9.3. North America: Country Analysis
  • 9.3.1. United States Cell Viability Assays Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By End Use
  • 9.3.2. Mexico Cell Viability Assays Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By End Use
  • 9.3.3. Canada Cell Viability Assays Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By End Use

10. South America Cell Viability Assays Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Application
  • 10.2.3. By End Use
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Cell Viability Assays Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By End Use
  • 10.3.2. Argentina Cell Viability Assays Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By End Use
  • 10.3.3. Colombia Cell Viability Assays Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By End Use

11. Middle East and Africa Cell Viability Assays Market Outlook

• 11.1. Market Size & Forecast
  • 11.1.1. By Value
• 11.2. Market Share & Forecast
  • 11.2.1. By Product
  • 11.2.2. By Application
  • 11.2.3. By End Use
  • 11.2.4. By Country
• 11.3. MEA: Country Analysis
  • 11.3.1. South Africa Cell Viability Assays Market Outlook
    • 11.3.1.1. Market Size & Forecast
      • 11.3.1.1.1. By Value
    • 11.3.1.2. Market Share & Forecast
      • 11.3.1.2.1. By Product
      • 11.3.1.2.2. By Application
      • 11.3.1.2.3. By End Use
  • 11.3.2. Saudi Arabia Cell Viability Assays Market Outlook
    • 11.3.2.1. Market Size & Forecast
      • 11.3.2.1.1. By Value
    • 11.3.2.2. Market Share & Forecast
      • 11.3.2.2.1. By Product
      • 11.3.2.2.2. By Application
      • 11.3.2.2.3. By End Use
  • 11.3.3. UAE Cell Viability Assays Market Outlook
    • 11.3.3.1. Market Size & Forecast
      • 11.3.3.1.1. By Value
    • 11.3.3.2. Market Share & Forecast
      • 11.3.3.2.1. By Product
      • 11.3.3.2.2. By Application
      • 11.3.3.2.3. By End Use

12. Market Dynamics

• 12.1. Drivers
• 12.2. Challenges

13. Market Trends & Developments

• 13.1. Recent Developments
• 13.2. Product Launches
• 13.3. Mergers & Acquisitions

14. Global Cell Viability Assays Market: SWOT Analysis

15. Porter's Five Forces Analysis

• 15.1. Competition in the Industry
• 15.2. Potential of New Entrants
• 15.3. Power of Suppliers
• 15.4. Power of Customers
• 15.5. Threat of Substitute Product

16. PESTLE Analysis

17. Competitive Landscape

• 17.1. Thermo Fisher Scientific, Inc
  • 17.1.1. Business Overview
  • 17.1.2. Product & Service Offerings
  • 17.1.3. Recent Developments
  • 17.1.4. Financials (If Listed)
  • 17.1.5. Key Personnel
  • 17.1.6. SWOT Analysis
• 17.2. Agilent Technologies, Inc.
• 17.3. Bio-Rad Laboratories, Inc.
• 17.4. Merck KGaA
• 17.5. PerkinElmer Inc.
• 17.6. Promega Corporation
• 17.7. Biotium Inc.
• 17.8. Creative Bioarra
• 17.9. Abcam plc
• 17.10.Charles River Laboratories International, Inc

18. Strategic Recommendations

19. About Us & Disclaimer